MRL 2002-003 An open label dose escalating efficacy study of implitapide at daily doses of 10 mg, 15 mg, 20mg, 25 mg, 30mg, 35 mg, and 40 mg in patients with hypertriglyceridemia (HTG) on maximal, concurrent triglyceride lowering therapy.